EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes

Indira Pla iD, Botond L Szabolcs iD, Petra Nikolett Péter, Zsuzsanna Ujfaludi, Yonghyo Kim, Peter Horvatovich, Aniel Sanchez, Krzysztof Pawlowski, Elisabet Wieslander, Magdalena Kuras, Jimmy Rodriguez Murillo, Jéssica Guedes und 24 weitere

International Journal of Dermatology · 2025

DOI: 10.1111/ijd.17586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Indira Pla und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Faculty of Engineering, LTH, Lund University, Lund, Sweden. Hauptthemen laut MEDLINE: Melanoma, Ferroptosis, Skin Neoplasms, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Fru Berta Kamprads Stiftelse, EU's Horizon 2020 research and innovation program, Semmelweis Egyetem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune‐checkpoint‐based therapies still poses a significant problem.

Objective

Here, we mine large‐scale MM proteogenomic data to identify druggable targets and forecast treatment efficacy and resistance.

Methods

Leveraging protein profiles from established MM subtypes and molecular structures of 82 cancer treatment drugs, we identified nine candidate hub proteins, mTOR, FYN, PIK3CB, EGFR, MAPK3, MAP4K1, MAP2K1, SRC, and AKT1, across five distinct MM subtypes. These proteins are potential drug targets applicable to one or multiple MM subtypes. Additionally, by integrating proteogenomic profiles obtained from MM subtypes with MM cell line dependency and drug sensitivity data, we identified a total of 162 potentially targetable genes. Lastly, we identified 20 compounds exhibiting potential drug impact in at least one melanoma subtype.

Results

Employing these unbiased approaches, we have uncovered compounds targeting ferroptosis demonstrating a striking 30× fold difference in sensitivity among different subtypes.

Conclusions

Our results suggest innovative and novel therapeutic strategies by stratifying melanoma samples through proteomic profiling, offering a spectrum of novel therapeutic interventions and prospects for combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaFerroptosisSkin NeoplasmsHistone Deacetylase InhibitorsProtein Kinase InhibitorsAntineoplastic AgentsHumansCell Line, TumorDrug Resistance, NeoplasmProteomicsMolecular Targeted Therapy

Stichwörter der Autor:innen

HDACRTK inhibitordrug target predictionferroptosismalignant melanomaskin cancer

Substanzen

Histone Deacetylase InhibitorsProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Faculty of Engineering, LTH, Lund University, Lund, Sweden.
  • European Cancer Moonshot Lund Center, Lund, Sweden.
  • HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
  • Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • Department of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
  • MTA-SE Lendület "Momentum" Dermatology Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.

ORCID-Profile: Indira Pla, Botond L Szabolcs, Dorottya M P Pál, Jeovanis Gil, Beáta Szeitz, Lajos V Kemény

Förderung

  • Fru Berta Kamprads Stiftelse
  • EU's Horizon 2020 research and innovation program
  • Semmelweis Egyetem
  • Hungarian Scientific Research Fund
  • Lendület "Momentum" grant from the Hungarian Academy of Sciences
  • NCI NIH HHS
  • Swedish Pharmaceutical Society
  • National Cancer Institute

Zitieren

APA

Pla, I., Szabolcs, B. L., Péter, P. N., Ujfaludi, Z., Kim, Y., Horvatovich, P., Sanchez, A., Pawlowski, K., Wieslander, E., Kuras, M., Murillo, J. R., Guedes, J., Pál, D. M. P., Ascsillán, A. A., Betancourt, L. H., Németh, I. B., Gil, J., de Almeida, N. P., Szeitz, B., …, & Kemény, L. V. (2025). Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes. International Journal of Dermatology. https://doi.org/10.1111/ijd.17586

Vancouver

Pla I, Szabolcs BL, Péter PN, Ujfaludi Z, Kim Y, Horvatovich P, et al. Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes. International Journal of Dermatology. 2025. doi:10.1111/ijd.17586

BibTeX
@article{Pla2025,
  author = {Pla, Indira and Szabolcs, Botond L and Péter, Petra Nikolett and Ujfaludi, Zsuzsanna and Kim, Yonghyo and Horvatovich, Peter and Sanchez, Aniel and Pawlowski, Krzysztof and Wieslander, Elisabet and Kuras, Magdalena and Murillo, Jimmy Rodriguez and Guedes, Jéssica and Pál, Dorottya M P and Ascsillán, Anna A and Betancourt, Lazaro Hiram and Németh, István Balázs and Gil, Jeovanis and de Almeida, Natália Pinto and Szeitz, Beáta and Szadai, Leticia and Doma, Viktória and Woldmar, Nicole and Bartha, Áron and Pahi, Zoltan and Pankotai, Tibor and Győrffy, Balázs and Szasz, A Marcell and Domont, Gilberto and Nogueira, Fábio and Kwon, Ho Jeong and Appelqvist, Roger and Kárpáti, Sarolta and Fenyö, David and Malm, Johan and Marko-Varga, György and Kemény, Lajos V},
  title = {Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes},
  journal = {International Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ijd.17586}
}
Kostenlos starten →